5 Zarling AL, Ficarro SB, White FM, et al. Phosphorylated peptides are naturally processed and presented by major histocompatibility complex class I molecules in vivo. J Exp Med 2000;192:1755–62. 6 Zarling AL, Polefrone JM, Evans AM, et al. Identification of class I MHC- associated phosphopeptides as targets for cancer immunotherapy. Proc Natl Acad Sci U S A 2006;103:14889–94. 7 Zarling AL, Obeng RC, Desch AN, et al. MHC- restricted phosphopeptides from insulin receptor substrate-2 and CDC25b offer broad- based immunotherapeutic agents for cancer. Cancer Res 2014;74:6784–95. 8 Dearth RK, Cui X, Kim H- J, et al. Oncogenic transformation by the signaling adaptor proteins insulin receptor substrate (IRS)-1 and IRS-2. Cell Cycle 2007;6:705–13. 9 Gorgisen G, Gulacar IM, Ozes ON. The role of insulin receptor substrate (IRS) proteins in oncogenic transformation. Cell Mol Biol 2017;63:1–5. 10 Dearth RK, Cui X, Kim H- J, et al. Mammary tumorigenesis and metastasis caused by overexpression of insulin receptor substrate 1 (IRS-1) or IRS-2. Mol Cell Biol 2006;26:9302–14.